Last reviewed · How we verify
CG001419
At a glance
| Generic name | CG001419 |
|---|---|
| Sponsor | Cullgen Australia Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects (PHASE1)
- A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CG001419 CI brief — competitive landscape report
- CG001419 updates RSS · CI watch RSS
- Cullgen Australia Pty Ltd portfolio CI